Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
In June 2024, the New England Journal of Medicine published results from SURMOUNT-OSA, the Phase 3 trial that established tirzepatide as the first incretin-based therapy with documented efficacy in obstructive sleep apnea. Until this study, OSA management had been dominated by CPAP machines and weight loss interventions; SURMOUNT-OSA suggested a pharmacologic alternative for the substantial overlap population of OSA patients with obesity.
Why OSA and Obesity Share a Pathway
Obstructive sleep apnea is the partial or complete collapse of the upper airway during sleep, causing repeated drops in blood oxygen and disrupted sleep architecture. Visceral and pharyngeal adiposity are major contributors: excess soft tissue around the airway, combined with reduced lung volume and altered ventilatory control, creates the conditions for collapse. Roughly 70% of moderate-to-severe OSA patients have a body mass index ≥30 kg/m². Reducing body weight can directly improve airway patency — the mechanistic rationale for testing a powerful weight-loss medication in this population.
The SURMOUNT-OSA Design
SURMOUNT-OSA enrolled adults with moderate-to-severe obstructive sleep apnea (apnea-hypopnea index, or AHI, ≥15 events per hour) and obesity (BMI ≥30). The trial ran across two distinct cohorts based on CPAP use:
- Trial 1: Participants not using positive airway pressure therapy at baseline.
- Trial 2: Participants currently on PAP therapy and continuing it.
In both arms, patients were randomized to weekly subcutaneous tirzepatide (titrated up to maximum tolerated dose, 10 or 15 mg) or placebo, for 52 weeks. The primary endpoint was the change in AHI from baseline to week 52.
Tirzepatide produced a mean reduction in AHI of approximately 25-30 events per hour (a relative reduction of up to 62.8% versus baseline) compared to roughly 5 events per hour with placebo. In the PAP-non-using arm, the mean AHI fell from approximately 51 to 14 events per hour with tirzepatide.
Up to 51.5% of tirzepatide-treated participants met criteria for OSA disease resolution (AHI <5, or AHI <15 with no significant daytime symptoms) — a substantial proportion previously achievable only with surgical intervention or sustained, dramatic weight loss.
Beyond AHI, tirzepatide produced statistically significant improvements in: body weight (mean reductions of 17-20%), hypoxic burden (a measure of nighttime oxygen desaturation), high-sensitivity CRP (systemic inflammation), systolic blood pressure, and patient-reported sleep-related outcomes including the Epworth Sleepiness Scale and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep scales.
Mechanism: Beyond Weight Loss Alone?
The most interesting interpretive question is whether the AHI improvements were driven entirely by weight reduction, or whether tirzepatide produces additional anti-inflammatory and metabolic benefits relevant to OSA pathophysiology. Statistical modeling in the SURMOUNT-OSA paper suggested that weight loss accounted for the majority — but not all — of the AHI improvement. Reductions in CRP and blood pressure point to systemic effects that could plausibly contribute to airway and breathing improvements independent of weight.
Implications for Practice
SURMOUNT-OSA's publication contributed to the FDA's approval of tirzepatide (under the brand name Zepbound) for moderate-to-severe OSA in adults with obesity in late 2024 — making it the first medication approved for this indication. Practical implications:
- Tirzepatide is now an evidence-based option for OSA in patients with obesity who have not tolerated or responded adequately to CPAP.
- It does not replace CPAP for patients with severe OSA who require immediate airway management, but may complement or eventually substitute for some patients as they lose weight.
- Insurance coverage for OSA-indication tirzepatide is evolving rapidly; many plans now cover the indication that previously refused weight-management coverage.
Tolerability
The safety profile in SURMOUNT-OSA mirrored prior tirzepatide trials: predominantly gastrointestinal adverse events (nausea, diarrhea, constipation, vomiting) most common during dose titration. Discontinuation rates were low. The boxed warnings for thyroid C-cell tumors and contraindications for personal or family history of medullary thyroid carcinoma or MEN2 still apply.
What This Means at Irvine Health
For patients evaluating peptide therapy options whose health picture includes both obesity and obstructive sleep apnea, tirzepatide now has a uniquely strong evidence base — addressing two major comorbidities with a single weekly injection. Any consideration of tirzepatide for OSA at our practice begins with a full physician evaluation including sleep history, prior CPAP trial, and comorbid risk assessment. SURMOUNT-OSA does not change the requirement for individualized clinical decision-making, but it adds a powerful new evidence layer to the conversation.
References
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. DOI: 10.1056/NEJMoa2404881.
- Eli Lilly and Company. Tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution. Press release, April 17, 2024.
- U.S. Food and Drug Administration. FDA approves Zepbound (tirzepatide) for adults with moderate-to-severe obstructive sleep apnea and obesity. December 2024.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216 (SURMOUNT-1).